Home
About us
Our History
Mission
Executive Team
Board of Directors
Pipeline
Overview
CM24
NT219
IM1240
Publications
Investors
Overview
News & Events
Press Releases
SEC Filings
Shareholders’ Meetings
Email Alerts
Corporate Governance
Contact us
menu
Home
About us
Pipeline
Investors
Contact Us
To Top
Portfolio:
news & events
Categories
News and Events
Events
News
Publications
CM-24
more about CM-24
more about NT-219
NT-219
Posts
Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.
Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.
Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.
Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.
Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023
CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells
Purple Biotech to participate and Present at the Jefferies London Healthcare Conference
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
Purple Biotech to participate in a leadership call by Chardan Capital Markets LLC. – Click here to replay
Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors
testing
By
afri-can
in Mar 13, 2023
sdfsdfdsf
Read more
Skip to content
Open toolbar
Accessibility Tools
Accessibility Tools
Increase Text
Increase Text
Decrease Text
Decrease Text
Grayscale
Grayscale
High Contrast
High Contrast
Negative Contrast
Negative Contrast
Light Background
Light Background
Links Underline
Links Underline
Readable Font
Readable Font
Reset
Reset